

*E1*  
*control*  
R<sup>6</sup> is methyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, pentyl, hexyl, or C<sub>3-6</sub>-cycloalkyl,

R<sup>7</sup> is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, pentyl, hexyl, C<sub>3-6</sub>-cycloalkyl, or C<sub>2-4</sub>-acyl, or

R<sup>6</sup> and R<sup>7</sup> together with the nitrogen between them form a 5- or 6-membered, saturated or unsaturated ring containing 0, 1, or 2 additional heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, wherein each additional nitrogen atom is unsubstituted or substituted by methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, or *tert*-butyl, or R<sup>6</sup> and R<sup>7</sup> together with the nitrogen between them form phthalimido;

R<sup>3</sup> is hydrogen, halogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, pentyl, hexyl, C<sub>1-6</sub>-alkoxy, -CF<sub>3</sub>, or -OCF<sub>3</sub>;

R<sup>4</sup> is hydrogen, halogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, pentyl, or hexyl; and

R<sup>5</sup> is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, pentyl, hexyl, C<sub>1-6</sub>-alkoxy, halogen, -CF<sub>3</sub>, or -OCF<sub>3</sub>;

or a pharmaceutically acceptable salt thereof.--

*E2*  
--29. (Amended) A compound selected from the group consisting of:

- (a) 2-(6-bromo-3-dimethylamino-2-methylphenylimino)imidazolidine,
- (b) 2-(2-methyl-3-phthalimidophenylimino)imidazolidine,
- (c) 2-(3-acetylamino-6-chlorophenylimino)imidazolidine,
- (d) 2-(3-amino-2-methylphenylimino)imidazolidine,

- E2  
Copy
- (e) 2-(3-amino-4,6-dibromo-2-methylphenylimino)imidazolidine,
  - (f) 2-(3-amino-4-methylphenylimino)imidazolidine,
  - (g) 2-(4,6-dibromo-3-dimethylamino-2-methylphenylimino)imidazolidine,
  - (h) 2-(4-bromo-3-dimethylamino-2-methylphenylimino)imidazolidine,
  - (i) 2-(6-chloro-3-dimethylamino-2-methylphenylimino)imidazolidine, and
  - (j) 2-(6-chloro-3-phthalimidophenylimino)imidazolidine,

or a pharmaceutically acceptable salt thereof.--

--34. (Amended) A pharmaceutical composition comprising:

(a) a compound selected from the group consisting of:

2-(3-dimethylamino-2-methylphenylimino)imidazolidine,

2-(6-bromo-3-dimethylamino-2-methylphenylimino)imidazolidine,

2-(5-amino-2-chloro-4-dimethylamino-2-methylphenylimino)imidazolidine, and

2-(3-amino-2-methylphenylimino)imidazolidine,

or a pharmaceutically acceptable salt thereof, and

(b) one or more pharmaceutically acceptable excipients, adjuvants, carriers, or preservatives.--

E3  
V3

--35. (Amended) A pharmaceutical composition comprising 2-(3-dimethylamino-2-methylphenylimino)imidazolidine, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients, adjuvants, carriers, or preservatives.--

--38. (Amended) A pharmaceutical composition comprising:

(a) a compound selected from the group consisting of:

E 4  
2-(3-dimethylamino-2-methylphenylimino)imidazolidine,

2-(6-bromo-3-dimethylamino-2-methylphenylimino)imidazolidine,

2-(2-methyl-3-phthalimidophenylimino)imidazolidine,

2-(3-acetylamino-6-chlorophenylimino)imidazolidine,

2-(3-amino-2-methylphenylimino)imidazolidine,

2-(3-amino-4,6-dibromo-2-methylphenylimino)imidazolidine,

2-(3-amino-4-methylphenylimino)imidazolidine,

2-(4,6-dibromo-3-dimethylamino-2-methylphenylimino)imidazolidine,

2-(4-bromo-3-dimethylamino-2-methylphenylimino)imidazolidine,


2-(6-chloro-3-dimethylamino-2-methylphenylimino)imidazolidine,

2-(6-chloro-3-phthalimidophenylimino)imidazolidine,

or a pharmaceutically acceptable salt thereof; and

(b) one or more pharmaceutically acceptable excipients, adjuvants, carriers, or preservatives.-

--39. (Twice amended) A pharmaceutical composition comprising a compound of the formula (II)



wherein:

$R^1$  is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, pentyl, hexyl,  $C_{3-6}$ -cycloalkyl,  $C_{1-6}$ -alkoxy, halogen,  $-CF_3$ , or  $-OCF_3$ ;

$R^2$  is  $-NR^6R^7$ , wherein

$R^6$  is ethyl,

$R^7$  is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, pentyl, hexyl,  $C_{3-6}$ -cycloalkyl, or  $C_{2-4}$ -acyl, or

$R^6$  and  $R^7$  together with the nitrogen between them form a 5- or 6-membered, saturated or unsaturated ring containing 0, 1, or 2 additional heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, wherein each additional nitrogen atom is unsubstituted or substituted by methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, or *tert*-butyl, or  $R^6$  and  $R^7$  together with the nitrogen between them form phthalimido;

$R^3$  is hydrogen, halogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, pentyl, hexyl,  $C_{1-6}$ -alkoxy,  $-CF_3$ , or  $-OCF_3$ ;


$R^4$  is hydrogen, halogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, pentyl, or hexyl; and

$R^5$  is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, pentyl, hexyl,  $C_{1-6}$ -alkoxy, halogen,  $-CF_3$ , or  $-OCF_3$ ;

or a pharmaceutically acceptable salt thereof; and

one or more pharmaceutically acceptable excipients, adjuvants, carriers, or preservatives.--

--51. (Amended) A compound of the formula (II)



wherein:

R<sup>1</sup> is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, pentyl, hexyl, C<sub>3-6</sub>-cycloalkyl, C<sub>1-6</sub>-alkoxy, halogen, -CF<sub>3</sub>, or -OCF<sub>3</sub>;

R<sup>2</sup> is -NR<sup>6</sup>R<sup>7</sup>, wherein R<sup>6</sup> and R<sup>7</sup> together with the nitrogen between them form a 5- or 6-membered, saturated or unsaturated ring containing 0, 1, or 2 additional heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, wherein each additional nitrogen atom is unsubstituted or substituted by methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, or *tert*-butyl, or R<sup>6</sup> and R<sup>7</sup> together with the nitrogen between them form phthalimido;


R<sup>3</sup> is hydrogen, halogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, pentyl, hexyl, C<sub>1-6</sub>-alkoxy, -CF<sub>3</sub>, or -OCF<sub>3</sub>;

R<sup>4</sup> is hydrogen, halogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, pentyl, or hexyl; and

R<sup>5</sup> is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, pentyl, hexyl, C<sub>1-6</sub>-alkoxy, halogen, -CF<sub>3</sub>, or -OCF<sub>3</sub>;

or a pharmaceutically acceptable salt thereof.--

--52. (Amended) A compound of the formula (II)



(II)

wherein:

$R^1$  is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, cyclopropyl,  $C_{1-4}$ -alkoxy, halogen,  $-CF_3$ , or  $-OCF_3$ ;

$R^2$  is  $-NR^6R^7$ , wherein  $R^6$  and  $R^7$  together with the nitrogen between them form phthalimido;


$R^3$  is hydrogen, halogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl,  $C_{1-4}$ -alkoxy,  $-CF_3$ , or  $-OCF_3$ ;

$R^4$  is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, or halogen; and,

$R^5$  is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl,  $C_{1-4}$ -alkoxy, halogen,  $-CF_3$ , or  $-OCF_3$ ;

or a pharmaceutically acceptable salt thereof.--

--53. (Amended) A compound of the formula (II)



(II)

wherein:

$R^1$  is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, cyclopropyl,  $C_{1-3}$ -alkoxy, halogen, or  $-CF_3$ ;

$R^2$  is  $-NR^6R^7$ , wherein  $R^6$  and  $R^7$  together with the nitrogen between them form phthalimido;


*EB*  
*cont'd*  
 $R^3$  is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl,  $C_{1-3}$ -alkoxy, halogen, or  $-CF_3$ ;

$R^4$  is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, or halogen; and,

$R^5$  is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl,  $C_{1-3}$ -alkoxy, halogen, or  $-CF_3$ ;

or a pharmaceutically acceptable salt thereof.--

--54. (Amended) A compound of the formula (II)



wherein:

$R^1$  is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, or halogen;

$R^2$  is  $-NR^6R^7$ , wherein  $R^6$  and  $R^7$  together with the nitrogen between them form phthalimido;

$R^3$  is hydrogen, methyl, fluorine, chlorine, or bromine;

$R^4$  is hydrogen; and

$R^5$  is hydrogen, methyl, chlorine, or bromine;

or a pharmaceutically acceptable salt thereof.--

Please add new claim 70 as follows.

*EB*  
--70. (new) 2-(3-dimethylamino-2-methylphenylimino)imidazolidine, or a pharmaceutically acceptable salt thereof.--